Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam

Psychopharmacology

Volumn 139, Issue 3, 1998, Pages 269-273

  Yasui, Norio ^a   Kondo, Tsuyoshi ^a   Otani, Koichi ^b   Furukori, Hanako ^a   Kaneko, Sunao ^a   Ohkubo, Tadashi ^c   Nagasaki, Takako ^c   Sugawara, Kazunobu ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Alprazolam; CYP3A4; Interaction; Itraconazole

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 INHIBITOR; ITRACONAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; ITRACONAZOLE; MALE; PSYCHOMOTOR PERFORMANCE;

EID: 0031655326     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050715     Document Type: Article

References (23)

1. Ahonen J, Olkkola KT, Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272
2. Garzone PD, Kroboth PD (1989) Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16:337-364
3. Gascon M-P, Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578
4. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 24: 453-471
5. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J (1977) Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry 134: 559-562
6. Greenblatt DJ, Harmatz JS, Shader RI (1993) Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 50:715-722
7. Greenblatt DJ, von Moltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI (1995) Interaction of triazolam and ketoconazole. Lancet 345:191
8. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ (1995) Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 58:127-131
9. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28
10. Lingjaerde O, Ahlfors UG, Bech P, Dencher SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76[Suppl 334]:11-100
11. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997) Grapefruit juice increases felodipine oral availability in human by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553
12. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Otani K, Kaneko S (1997) Determination of alprazolam and α-hydroxyalprazolam in plasma by high-performance liquid chromatography. Anal Sci 13:245-249
13. Neuvonen PJ, Varhe A, Olkkola KT (1996) The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin Pharmacol Ther 60:326-331
14. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
15. Otani K, Yasui N, Furukori H, Kaneko S, Tasaki H, Ohkubo T, Nagasaki T, Sugawara K, Hayashi K (1997) Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. Int Clin Psychopharmacol 12:153-157
16. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. 3rd edn. Williams & Wilkins, Baltimore
17. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics keloconazole or itraconazole. Clin Pharmacol Ther 56: 601-607
18. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31
19. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI (1996a) Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interaction in vivo. J Clin Psychopharmacol 16:104-112
20. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996b) Triazolam biotransformation by human liver microcosms in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379
21. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
22. Wilkinson GR (1996) Cytochrome P4503 A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490
23. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514-519